Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Silver proteinate is an organic complex of silver and protein (typically albumin) that acts as a topical antiseptic and nasal decongestant. It has broad antibacterial and anti-inflammatory activity and was historically used to treat infections such as gonorrhea before the advent of antibiotics[1][2][5]. Silver proteinate is also widely used in histology and electron microscopy for staining carbohydrates (e.g., glycogen) and nerve tissue due to its ability to gradually release silver ions[2][8]. Its mechanism of action involves the slow release of bactericidal silver ions that disrupt microbial cell membranes by binding to membrane proteins and peptidoglycans, leading to loss of structural integrity[6]. The drug was first introduced for therapeutic use in 1897 by Arthur Eichengrün at Bayer[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on silver proteinate.